-+ 0.00%
-+ 0.00%
-+ 0.00%

Fu Hong Han Lin (02696): Futurin® (vorvicil citrate capsules) was included in the national medical insurance drug catalogue

Zhitongcaijing·12/07/2025 10:49:02
Listen to the news

Zhitong Finance App News, Fu Hong Han Lin (02696) issued an announcement. Recently, Futunine® (vorvicil citrate capsules) was included in the “National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalogue (2025)”. The included indications are combined with fluvizil for hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) -negative adult breast cancer patients with recurrent or metastatic breast cancer. The new version of the National Medical Insurance Drug Catalogue will be officially implemented on January 1, 2026.

Fortokine® is an innovative CDK4/6 small molecule inhibitor introduced with permission from the company. In May 2025, it was approved for marketing in China. The first approved indication was for patients with recurrent or metastatic adult breast cancer with positive hormone receptor (HR) positive and human epidermal growth factor receptor 2 (HER2) negative after previous endocrine treatment; in September 2025, Futunin® was approved for use in China as an additional indication for hormone receptor (HR) positive and human epidermal growth factor receptor 2 (HER2) -negative adult breast cancer patients with locally advanced or metastatic breast cancer patients with aromatase inhibitors Use as initial endocrine therapy .